Clinical Trial Update: Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of IPG11406 in moderately to severely active ulcerative colitis. The study status is NOT_YET_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• IPG11406

Snippet

Sponsor: Nanjing Immunophage Biotech Co., Ltd | Conditions: Moderately to Severely Active Ulcerative Colitis (UC) | Phase 2 | Status: NOT_YET_RECRUITING